These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28066420)

  • 21. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma.
    Daneshmandi S; Wegiel B; Seth P
    Cancers (Basel); 2019 Mar; 11(4):. PubMed ID: 30934955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy.
    Shevtsov M; Sato H; Multhoff G; Shibata A
    Front Oncol; 2019; 9():156. PubMed ID: 30941308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.
    Dosset M; Vargas TR; Lagrange A; Boidot R; Végran F; Roussey A; Chalmin F; Dondaine L; Paul C; Lauret Marie-Joseph E; Martin F; Ryffel B; Borg C; Adotévi O; Ghiringhelli F; Apetoh L
    Oncoimmunology; 2018; 7(6):e1433981. PubMed ID: 29872568
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions.
    Sugita S; Usui Y; Horie S; Futagami Y; Aburatani H; Okazaki T; Honjo T; Takeuchi M; Mochizuki M
    Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2862-70. PubMed ID: 19182257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of ionising radiation with hyperthermia increases the immunogenic potential of B16-F10 melanoma cells in vitro and in vivo.
    Werthmöller N; Frey B; Rückert M; Lotter M; Fietkau R; Gaipl US
    Int J Hyperthermia; 2016; 32(1):23-30. PubMed ID: 26754406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor.
    Shi L; Chen L; Wu C; Zhu Y; Xu B; Zheng X; Sun M; Wen W; Dai X; Yang M; Lv Q; Lu B; Jiang J
    Clin Cancer Res; 2016 Mar; 22(5):1173-1184. PubMed ID: 26933175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The Expression and Biological Significance of PD-L1 on Lung Cancer Cell Lines.].
    Chen C; Mu C; Qu Q; Zhu Y; Sun J; Zhang X; Huang J
    Zhongguo Fei Ai Za Zhi; 2009 Aug; 12(8):859-63. PubMed ID: 20719171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
    Kroon P; Gadiot J; Peeters M; Gasparini A; Deken MA; Yagita H; Verheij M; Borst J; Blank CU; Verbrugge I
    Cancer Immunol Immunother; 2016 Jun; 65(6):753-63. PubMed ID: 27160390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells.
    Eppihimer MJ; Gunn J; Freeman GJ; Greenfield EA; Chernova T; Erickson J; Leonard JP
    Microcirculation; 2002 Apr; 9(2):133-45. PubMed ID: 11932780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment.
    Krönig H; Kremmler L; Haller B; Englert C; Peschel C; Andreesen R; Blank CU
    Eur J Haematol; 2014 Mar; 92(3):195-203. PubMed ID: 24175978
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.
    Rodić N; Anders RA; Eshleman JR; Lin MT; Xu H; Kim JH; Beierl K; Chen S; Luber BS; Wang H; Topalian SL; Pardoll DM; Taube JM
    Cancer Immunol Res; 2015 Feb; 3(2):110-5. PubMed ID: 25370533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down Regulation of c-FLIP
    Wang Y; Li JJ; Ba HJ; Wang KF; Wen XZ; Li DD; Zhu XF; Zhang XS
    Front Oncol; 2019; 9():857. PubMed ID: 31552181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
    Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
    Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
    Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
    J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 expression and prognostic impact in glioblastoma.
    Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
    Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer.
    Abiko K; Matsumura N; Hamanishi J; Horikawa N; Murakami R; Yamaguchi K; Yoshioka Y; Baba T; Konishi I; Mandai M
    Br J Cancer; 2015 Apr; 112(9):1501-9. PubMed ID: 25867264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical Evaluation of Recombinant Human IL15 Protein Fused with Albumin Binding Domain on Anti-PD-L1 Immunotherapy Efficiency and Anti-Tumor Immunity in Colon Cancer and Melanoma.
    Hsu FT; Liu YC; Tsai CL; Yueh PF; Chang CH; Lan KL
    Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines.
    Doi T; Ishikawa T; Okayama T; Oka K; Mizushima K; Yasuda T; Sakamoto N; Katada K; Kamada K; Uchiyama K; Handa O; Takagi T; Naito Y; Itoh Y
    Oncol Rep; 2017 Mar; 37(3):1545-1554. PubMed ID: 28112370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.
    Kluger HM; Zito CR; Barr ML; Baine MK; Chiang VL; Sznol M; Rimm DL; Chen L; Jilaveanu LB
    Clin Cancer Res; 2015 Jul; 21(13):3052-60. PubMed ID: 25788491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.